Transcatheter Arterial Embolization (TAE) of Cancer-Related Bleeding
Background and Objectives: Roughly 10% of cancer patients experience an episode of bleeding. The bleeding severity can range from occasional trivial bleeds to major bleeding. The treatment for the bleeding may vary, depending on the clinical condition and anatomical site, and may include various strategies, among which TAE is a cornerstone of major bleeding management. However, the existing literature on tumor hemorrhages is inconsistent. The objective of this multicenter retrospective cohort study was to evaluate the effectiveness and safety of arterial embolization in the treatment of tumor hemorrhages in patients with solid cancers. Materials and Methods: The data for patients with solid cancers undergoing TAE for the management of tumor hemorrhages from January 2020 to May 2023 were gathered. Results: A total of 92 patients with cancer-related bleeding were treated between January 2020 and May 2023. No bleeding was detected by X-ray angiography (XA) in 12 (13%) cases; therefore, a blind embolization was performed. The most common bleeding site was the liver (21.7%). A total of 66 tumor hemorrhages were spontaneous. The most commonly used embolic agent was polyvinyl alcohol (PVA) particles (30.4%). Technical success was achieved in 82 (89.1%) cases, with an 84.8% clinical success rate related to 14 cases of rebleeding. Proximal embolization was performed for 19 (20.7%) patients. Complications were recorded for 10 (10.9%) patients. The 30-day bleeding-related mortality was 15.2%. The technical success, clinical success, proximal embolization rate, and 30-day rebleeding were worse in the subset of patients undergoing TAE with coils. Conclusions: Transcatheter arterial embolization (TAE) represents a viable and potentially life-saving therapeutic approach in the management of tumor hemorrhages, demonstrating a notable effectiveness and safety. The TAE of bleeding tumors using coils resulted in a higher rate of non-superselective proximal embolization, with a trend toward lower clinical success rates and higher rebleeding episodes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
---|---|
Enthalten in: |
Medicina (Kaunas, Lithuania) - 59(2023), 7 vom: 18. Juli |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Minici, Roberto [VerfasserIn] |
---|
Links: |
---|
Themen: |
Bleeding |
---|
Anmerkungen: |
Date Completed 31.07.2023 Date Revised 01.08.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/medicina59071323 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM360120067 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM360120067 | ||
003 | DE-627 | ||
005 | 20231226082332.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/medicina59071323 |2 doi | |
028 | 5 | 2 | |a pubmed24n1200.xml |
035 | |a (DE-627)NLM360120067 | ||
035 | |a (NLM)37512135 | ||
035 | |a (PII)1323 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Minici, Roberto |e verfasserin |4 aut | |
245 | 1 | 0 | |a Transcatheter Arterial Embolization (TAE) of Cancer-Related Bleeding |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.07.2023 | ||
500 | |a Date Revised 01.08.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Background and Objectives: Roughly 10% of cancer patients experience an episode of bleeding. The bleeding severity can range from occasional trivial bleeds to major bleeding. The treatment for the bleeding may vary, depending on the clinical condition and anatomical site, and may include various strategies, among which TAE is a cornerstone of major bleeding management. However, the existing literature on tumor hemorrhages is inconsistent. The objective of this multicenter retrospective cohort study was to evaluate the effectiveness and safety of arterial embolization in the treatment of tumor hemorrhages in patients with solid cancers. Materials and Methods: The data for patients with solid cancers undergoing TAE for the management of tumor hemorrhages from January 2020 to May 2023 were gathered. Results: A total of 92 patients with cancer-related bleeding were treated between January 2020 and May 2023. No bleeding was detected by X-ray angiography (XA) in 12 (13%) cases; therefore, a blind embolization was performed. The most common bleeding site was the liver (21.7%). A total of 66 tumor hemorrhages were spontaneous. The most commonly used embolic agent was polyvinyl alcohol (PVA) particles (30.4%). Technical success was achieved in 82 (89.1%) cases, with an 84.8% clinical success rate related to 14 cases of rebleeding. Proximal embolization was performed for 19 (20.7%) patients. Complications were recorded for 10 (10.9%) patients. The 30-day bleeding-related mortality was 15.2%. The technical success, clinical success, proximal embolization rate, and 30-day rebleeding were worse in the subset of patients undergoing TAE with coils. Conclusions: Transcatheter arterial embolization (TAE) represents a viable and potentially life-saving therapeutic approach in the management of tumor hemorrhages, demonstrating a notable effectiveness and safety. The TAE of bleeding tumors using coils resulted in a higher rate of non-superselective proximal embolization, with a trend toward lower clinical success rates and higher rebleeding episodes | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a TAE | |
650 | 4 | |a bleeding | |
650 | 4 | |a cancer | |
650 | 4 | |a embolic agents | |
650 | 4 | |a embolization | |
650 | 4 | |a endovascular | |
650 | 4 | |a hemorrhage | |
650 | 4 | |a tumor | |
700 | 1 | |a Guzzardi, Giuseppe |e verfasserin |4 aut | |
700 | 1 | |a Venturini, Massimo |e verfasserin |4 aut | |
700 | 1 | |a Fontana, Federico |e verfasserin |4 aut | |
700 | 1 | |a Coppola, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Spinetta, Marco |e verfasserin |4 aut | |
700 | 1 | |a Piacentino, Filippo |e verfasserin |4 aut | |
700 | 1 | |a Pingitore, Armando |e verfasserin |4 aut | |
700 | 1 | |a Serra, Raffaele |e verfasserin |4 aut | |
700 | 1 | |a Costa, Davide |e verfasserin |4 aut | |
700 | 1 | |a Ielapi, Nicola |e verfasserin |4 aut | |
700 | 1 | |a Guerriero, Pasquale |e verfasserin |4 aut | |
700 | 1 | |a Apollonio, Biagio |e verfasserin |4 aut | |
700 | 1 | |a Santoro, Rita |e verfasserin |4 aut | |
700 | 1 | |a Mgjr Research Team |e verfasserin |4 aut | |
700 | 1 | |a Brunese, Luca |e verfasserin |4 aut | |
700 | 1 | |a Laganà, Domenico |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicina (Kaunas, Lithuania) |d 1998 |g 59(2023), 7 vom: 18. Juli |w (DE-627)NLM093687583 |x 1648-9144 |7 nnns |
773 | 1 | 8 | |g volume:59 |g year:2023 |g number:7 |g day:18 |g month:07 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/medicina59071323 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 59 |j 2023 |e 7 |b 18 |c 07 |